Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Akari Therapeutics Plc
AKTX | US
14.63
USD1.20
8.94%
AKTX | US
About Akari Therapeutics Plc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
14.63
Open
13.69
High
16.20
Low
13.40
Akari Therapeutics Plc a clinical-stage biopharmaceutical company focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities including paroxysmal nocturnal hemoglobinuria Guillain-Barré syndrome hematopoietic stem cell transplant-associated thrombotic microangiopathy and bullous pemphigoid as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London the United Kingdom.
View LessAKTX | US
Risk
937.7
Sharpe
0.23
Luna's Score
43/100
Recommendation
Sell
Luna says (AKTX | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
1316.0%1 month
937.7%3 months
8258.5%6 months
5912.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.07
Debt to equity
-0.27
Debt to assets
0.20
Ent. to EBITDA
-0.06
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-18.08M
MarketCap
177.68M
MarketCap(USD)
177.68M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-1.28K
Short ratio
2.26
Short perc.
0.41
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
26.17
Range1M
26.30
Range3M
29.20
Volumes: Market Activity
Rel. volume
0.12
Price X volume
3.87M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.06 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.07 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 8,258.47 | - | Riskier |
| Debt to Equity | -0.27 | -1.23 | Expensive |
| Debt to Assets | 0.20 | 0.25 | Cheaper |
| Market Cap | 177.68M | - | Emerging |
